Achieve Life Sciences Inc. (ACHV) and Seres Therapeutics Inc. (NASDAQ:MCRB) Comparing side by side

Achieve Life Sciences Inc. (NASDAQ:ACHV) and Seres Therapeutics Inc. (NASDAQ:MCRB) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achieve Life Sciences Inc. 3 0.00 N/A -3.96 0.00
Seres Therapeutics Inc. 5 6.35 N/A -2.34 0.00

Table 1 highlights Achieve Life Sciences Inc. and Seres Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows Achieve Life Sciences Inc. and Seres Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Achieve Life Sciences Inc. 0.00% -110% -89%
Seres Therapeutics Inc. 0.00% 235.9% -81.2%

Volatility & Risk

Achieve Life Sciences Inc. has a 2.06 beta, while its volatility is 106.00% which is more volatile than Standard and Poor’s 500. Seres Therapeutics Inc.’s 100.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 2 beta.

Liquidity

Achieve Life Sciences Inc.’s Current Ratio and Quick Ratio are 2.6 and 2.6 respectively. The Current Ratio and Quick Ratio of its competitor Seres Therapeutics Inc. are 1.6 and 1.6 respectively. Achieve Life Sciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Seres Therapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Achieve Life Sciences Inc. and Seres Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Achieve Life Sciences Inc. 0 0 0 0.00
Seres Therapeutics Inc. 0 0 4 3.00

Competitively Seres Therapeutics Inc. has an average target price of $14, with potential upside of 387.80%.

Insider and Institutional Ownership

Achieve Life Sciences Inc. and Seres Therapeutics Inc. has shares owned by institutional investors as follows: 32.2% and 61.9%. Achieve Life Sciences Inc.’s share owned by insiders are 2.7%. On the other hand, insiders owned about 0.4% of Seres Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achieve Life Sciences Inc. -3.17% -13.68% -58.97% 25.34% -44.72% 51.24%
Seres Therapeutics Inc. -9% -7.46% -55.32% -55.46% -62.76% -39.6%

For the past year Achieve Life Sciences Inc. has 51.24% stronger performance while Seres Therapeutics Inc. has -39.6% weaker performance.

Summary

Seres Therapeutics Inc. beats on 6 of the 8 factors Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.